Table 1.

Clinical trials of siRNA-containing nanoparticles targeting solid tumors following systemic administration

Name	Nanoparticle	Company	Molecular target(s)	Therapeutic indication	Route of administration	Status	Clinical trial identifier
CALAA-01	Tf-targeting PEGylated cyclodextrin-based NP	Calando Pharmaceuticals	RRM2 (cell proliferation)	Advanced solid tumors	Multiple 30 min iv infusion	Phase I Ongoing	NCT00689065
Atu027	PEGylated lipoplex-siRNA	Silence therapeutics	PKN3 (angiogenesis and metastasis)	Advanced solid tumors	Multiple 4 h iv infusion	Phase I Completed	NCT00938574
Atu027 + Gemcitabine				Advanced pancreatic cancer		Phase I Recruiting	NCT01808638
SNALP-PLK1	SNALP	Tekmira Pharmaceuticals Corporation	PLK1 (cell proliferation)	Primary and secondary liver metastasis	Multiple hepatic intra-arterial infusion	Phase I Completed	NCT01437007
				Solid tumor or lymphomas	Multiple iv infusion	Phase I Recruiting	NCT01262235
ALN-VSP02	SNALP	Alnylam Pharmaceuticals	KSP (cell proliferation) and VEGF (angiogenesis)	Advanced solid tumor with liver metastasis	Multiple 15 min iv infusion	Phase I Completed	NCT00882180
				Patients who have responded to ALN-VS02 in the first clinical trial		Phase I Completed	NCT01158079
siRNA-EphA2-DOPC	Non-PEGylated liposomes	M.D. Anderson Cancer Center	EPHA2 (cell proliferation)	Advanced solid tumors	Multiple 30 min iv-infusion	Phase I Not yet recruiting	NCT01591356

NP nanoparticle, RRM2 M2 subunit of ribonucleotide reductase, PKN3 protein kinase N3, PLK1 Polo-like kinase 1, KSP kinesin family member 11, VEGF vascular endothelial growth factor, EPHA2 ephrin type-A receptor 2